ETFMG Treatments, Testing and Advancements ETF GERM
Set alert
19.16 USD 0.00 0.00%
As of Sep 5, 3:53 PM ET
19.16 Day range 19.28
16.32 52-week range 20.20
- Open
- 19.28
- Prev close
- 19.16
- Mkt cap
- 9.59M
- Vol
- 4.83K
- Avg vol
- 1.20K
- EPS
- 2.57
- P/E
- 7.45
- Div yield
- 0.00%
More statistics
- Low
- 19.16
- High
- 19.28
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 18.93
- 200-d avg
- 18.53
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 7.45
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 18.93
- 200-day average
- 18.53
About ETFMG Treatments, Testing and Advancements ETF
Under normal circumstances, the fund invests at least 80% of its net assets in U.S.-listed equity securities or ADRs of Treatments, Testing and Advancements Companies. In general, the index seeks to be comprised of companies performing advancements in research, development, and commercialization of treatments or vaccines for infectious diseases, or engaged in the advancement of research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified.
News
- Mpox Variant Sparks Global Concern As Europe, China Ramp Up Screening
- FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
- Amplify ETFs to Liquidate Three ETFs
- Finding Opportunity in Unloved Healthcare ETFs
- Amplify's Christian Magoon on Purchase of ETFMG's ETFs
- This Week in ETFs: A Summer Slowdown
- Biotech ETFs in Focus on Covid Vaccines' Fall Rollout
- Can Health Care Stocks Outperform Again In 2023?
- Here's Why COVID-Themed ETFs May Come Back Under the Radar
- Biotech ETFs Slip After Novavax Cuts 2022 Guidance
Your note
Sign in to keep a note on GERM — it syncs with the Stock Master app.